FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 361:191-193 July 9, 2009 Number 2 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Migone, T.-S. PubMed Citation

In a world filled with pressing unmet medical needs, why would a physician want to protect against a disease that is rarely seen? Part of the answer can be deduced from the events of the fall of 2001. The deliberate release of anthrax spores on unsuspecting U.S. citizens in the wake of September 11 unsettled Americans who were already concerned about the weaponization of smallpox, Ebola and Marburg viruses, and other pathogens. The subsequent arrival of the highly pathogenic avian influenza virus, together with the recent swine influenza epidemic, has further underscored our vulnerability to infectious diseases, both deliberate and . . . [Full Text of this Article]

Source Information

From the Vaccine Research Center, National Institute of Allergy and Infectious Diseases, Bethesda, MD.

This article has been cited by other articles:

• (2009). A Monoclonal Antibody for Preventing and Treating Inhalational Anthrax. JWatch Infect. Diseases 2009: 1-1 [Full Text]